Cao Yang 4
4 · Humacyte, Inc. · Filed Sep 20, 2022
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Cao Yang
Chief Regulatory Officer
Transactions
- Award
Stock Options (right to buy)
2022-09-19+145,000→ 145,000 totalExercise: $3.73Exp: 2032-09-19→ Common Stock (145,000 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on September 19, 2023, after which 1/48 of the option will become exercisable on the 19th of each month through September 19, 2026.